Drug Profile


Alternative Names: PF-04950615; PF-4950615; RN-316

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Halozyme Therapeutics; Pfizer
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Nov 2016 Pfizer terminates the phase III SPIRE-2 trial for Cardiovascular disorders (Prevention, Adjunctive treatment) in Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Northern Ireland, Peru, Poland, Puerto Rico, Romania, Russia, Scotland, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom and USA, following the discontinuation of the global clinical development programme for bococizumab
  • 01 Nov 2016 University of California at San Francisco and Pfizer terminate the phase III B-HIVE trial for Cardiovascular disorders in USA, following the discontinuation of the global clinical development programme for bococizumab
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top